Table 1 Overview of demographics, medication, and clinical tests for controls and participants with Parkinson’s disease in both the DeNoPa and Iceberg cohort combined
From: Sleep stage mixing is associated with poor prognosis in early Parkinson’s disease
Controls | PD | p-value | ||
|---|---|---|---|---|
n | 158 | 280 | ||
Demographical data | ||||
Age [years] | μ ± σ | 63.9 ± 8.0 | 63.4 ± 9.6 | n.s. |
Sex (female) | % (n) | 40.6% (63) | 36.1% (101) | n.s. |
BMI [kg/m2] | μ ± σ | 26.2 ± 4.4 | 26.2 ± 4.3 | n.s. |
Parkinson’s disease duration [months] | μ ± σ | - | 21.1 ± 24.5 | - |
REM sleep behavior disorder | % (n) | 0.0% (0) | 25.2% (70) | <0.0001 |
Number of visits | μ ± σ | 2.1 ± 1.0 | 2.2 ± 1.2 | n.s. |
Follow-up duration at last visit [years] | μ ± σ | 3.6 ± 1.2 | 3.2 ± 1.5 | 0.037 |
Treatment | ||||
Antidepressants | % (n) | 4.6% (7) | 11.4% (32) | 0.03 |
Benzodiazepines | % (n) | 2.0% (3) | 1.4% (4) | n.s. |
LEDD [mg] | μ ± σ | - | 163.3 ± 248.5 | - |
Slope LEDD [mg per year] | μ ± σ | - | 100.7 ± 95.6 | - |
Motor and cognitive symptoms | ||||
MDS UPDRS III total score OFF (0–132) | μ ± σ | 2.3 ± 3.8 | 26.2 ± 10.6 | <0.0001 |
MDS UPDRS total score (0–199) | μ ± σ | 6.3 ± 6.7 | 42.0 ± 15.7 | <0.0001 |
Slope MDS UPDRS III total score [per year] | μ ± σ | 0.26 ± 1.2 | 1.2 ± 3.7 | 0.0013 |
Slope MDS UPDRS total score [per year] | μ ± σ | 0.9 ± 2.2 | 3.2 ± 5.6 | <0.0001 |
MoCA total score (0–30) | μ ± σ | 26.7 ± 2.6 | 26.5 ± 2.8 | n.s. |
Slope MoCA total score [per year] | μ ± σ | −0.086 ± 0.69 | −0.32 ± 1 | 0.027 |
